Aeglea Bio Therapeutics Stock Total Debt
| AGLEDelisted Stock | USD 0.59 0.01 1.72% |
Aeglea Bio Therapeutics fundamentals help investors to digest information that contributes to Aeglea Bio's financial success or failures. It also enables traders to predict the movement of Aeglea Stock. The fundamental analysis module provides a way to measure Aeglea Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aeglea Bio stock.
Aeglea |
Aeglea Bio Therapeutics Company Total Debt Analysis
Aeglea Bio's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Aeglea Bio Total Debt | 4.63 M |
Most of Aeglea Bio's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aeglea Bio Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
CompetitionBased on the latest financial disclosure, Aeglea Bio Therapeutics has a Total Debt of 4.63 M. This is 99.83% lower than that of the Biotechnology sector and 98.57% lower than that of the Health Care industry. The total debt for all United States stocks is 99.91% higher than that of the company.
Aeglea Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aeglea Bio's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aeglea Bio could also be used in its relative valuation, which is a method of valuing Aeglea Bio by comparing valuation metrics of similar companies.Aeglea Bio is currently under evaluation in total debt category among its peers.
Aeglea Fundamentals
| Return On Equity | -2.81 | |||
| Return On Asset | -0.42 | |||
| Operating Margin | (94.85) % | |||
| Current Valuation | 228.21 M | |||
| Shares Outstanding | 4.05 M | |||
| Shares Owned By Insiders | 2.40 % | |||
| Shares Owned By Institutions | 97.60 % | |||
| Number Of Shares Shorted | 128.62 K | |||
| Price To Earning | (2.41) X | |||
| Price To Book | 0.35 X | |||
| Price To Sales | 4.08 X | |||
| Revenue | 2.33 M | |||
| Gross Profit | (262 K) | |||
| EBITDA | (84.78 M) | |||
| Net Income | (83.81 M) | |||
| Cash And Equivalents | 73.68 M | |||
| Cash Per Share | 1.20 X | |||
| Total Debt | 4.63 M | |||
| Debt To Equity | 0.07 % | |||
| Current Ratio | 4.65 X | |||
| Book Value Per Share | (60.61) X | |||
| Cash Flow From Operations | (80.14 M) | |||
| Short Ratio | 2.84 X | |||
| Earnings Per Share | (74.15) X | |||
| Target Price | 17.5 | |||
| Number Of Employees | 69 | |||
| Beta | 2.57 | |||
| Market Capitalization | 45.59 M | |||
| Total Asset | 71.14 M | |||
| Retained Earnings | (425.62 M) | |||
| Working Capital | 47.6 M | |||
| Current Asset | 38.29 M | |||
| Current Liabilities | 2.52 M | |||
| Z Score | -5.56 | |||
| Net Asset | 71.14 M |
About Aeglea Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aeglea Bio Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aeglea Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aeglea Bio Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Other Consideration for investing in Aeglea Stock
If you are still planning to invest in Aeglea Bio Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aeglea Bio's history and understand the potential risks before investing.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |